Tags

Type your tag names separated by a space and hit enter

Review of current typhoid fever vaccines, cross-protection against paratyphoid fever, and the European guidelines.
Expert Rev Vaccines. 2017 10; 16(10):1029-1043.ER

Abstract

INTRODUCTION

Typhoid and paratyphoid fever remain a global health problem, which - in non-endemic countries - are mainly seen in travelers, particularly in VFRs (visiting friends and relatives), with occasional local outbreaks occurring. A rise in anti-microbial resistance emphasizes the role of preventive measures, especially vaccinations against typhoid and paratyphoid fever for travelers visiting endemic countries. Areas covered: This state-of-the-art review recapitulates the epidemiology and mechanisms of disease of typhoid and paratyphoid fever, depicts the perspective of non-endemic countries and travelers (VFRs), and collectively presents current European recommendations for typhoid fever vaccination. We provide a brief overview of available (and developmental) vaccines in Europe, present current data on cross-protection to S. Paratyphi, and aim to provide a background for typhoid vaccine decision-making in travelers. Expert commentary: European recommendations are not harmonized. Experts must assess vaccination of travelers based on current country-specific recommendations. Travel health practitioners should be aware of the issues surrounding vaccination of travelers and be motivated to increase awareness of typhoid and paratyphoid fever risks.

Authors+Show Affiliations

a Department of Infection and Immunity , Royal Free London Travel Health and Immunisation Clinic , London , UK.b Department of Medicine and Diagnostics , Swiss Tropical and Public Health Institute , Basel , Switzerland. c Epidemiology, Biostatistics and Prevention Institute , University of Zurich , Zurich , Switzerland.d Department of Clinical Medicine , University of Helsinki , Helsinki , Finland. e Inflammation Center, Division of Infectious Diseases , Helsinki University Hospital , Helsinki , Finland. f Unit of Infectious Diseases , Karolinska Institutet , Stockholm , Sweden.

Pub Type(s)

Journal Article
Review
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

28856924

Citation

Zuckerman, Jane N., et al. "Review of Current Typhoid Fever Vaccines, Cross-protection Against Paratyphoid Fever, and the European Guidelines." Expert Review of Vaccines, vol. 16, no. 10, 2017, pp. 1029-1043.
Zuckerman JN, Hatz C, Kantele A. Review of current typhoid fever vaccines, cross-protection against paratyphoid fever, and the European guidelines. Expert Rev Vaccines. 2017;16(10):1029-1043.
Zuckerman, J. N., Hatz, C., & Kantele, A. (2017). Review of current typhoid fever vaccines, cross-protection against paratyphoid fever, and the European guidelines. Expert Review of Vaccines, 16(10), 1029-1043. https://doi.org/10.1080/14760584.2017.1374861
Zuckerman JN, Hatz C, Kantele A. Review of Current Typhoid Fever Vaccines, Cross-protection Against Paratyphoid Fever, and the European Guidelines. Expert Rev Vaccines. 2017;16(10):1029-1043. PubMed PMID: 28856924.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Review of current typhoid fever vaccines, cross-protection against paratyphoid fever, and the European guidelines. AU - Zuckerman,Jane N, AU - Hatz,Christoph, AU - Kantele,Anu, PY - 2017/9/1/pubmed PY - 2018/5/16/medline PY - 2017/9/1/entrez KW - Paratyphoid fever KW - Ty21a KW - Vi capsular polysaccharide KW - typhoid fever KW - vaccine recommendations KW - visiting friends and relatives SP - 1029 EP - 1043 JF - Expert review of vaccines JO - Expert Rev Vaccines VL - 16 IS - 10 N2 - INTRODUCTION: Typhoid and paratyphoid fever remain a global health problem, which - in non-endemic countries - are mainly seen in travelers, particularly in VFRs (visiting friends and relatives), with occasional local outbreaks occurring. A rise in anti-microbial resistance emphasizes the role of preventive measures, especially vaccinations against typhoid and paratyphoid fever for travelers visiting endemic countries. Areas covered: This state-of-the-art review recapitulates the epidemiology and mechanisms of disease of typhoid and paratyphoid fever, depicts the perspective of non-endemic countries and travelers (VFRs), and collectively presents current European recommendations for typhoid fever vaccination. We provide a brief overview of available (and developmental) vaccines in Europe, present current data on cross-protection to S. Paratyphi, and aim to provide a background for typhoid vaccine decision-making in travelers. Expert commentary: European recommendations are not harmonized. Experts must assess vaccination of travelers based on current country-specific recommendations. Travel health practitioners should be aware of the issues surrounding vaccination of travelers and be motivated to increase awareness of typhoid and paratyphoid fever risks. SN - 1744-8395 UR - https://www.unboundmedicine.com/medline/citation/28856924/Review_of_current_typhoid_fever_vaccines_cross_protection_against_paratyphoid_fever_and_the_European_guidelines_ L2 - https://www.tandfonline.com/doi/full/10.1080/14760584.2017.1374861 DB - PRIME DP - Unbound Medicine ER -